Increasing healthcare costs in inflammatory bowel disease 2007–2020 in Sweden
Alimentary Pharmacology & Therapeutics · 2023
DOI: 10.1111/apt.17675 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2023. Written by Åsa H Everhov and 10 co-authors. Institution: Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease. Cited 18 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Kommunfullmäktige, Stockholms Stad, Vetenskapsrådet.
Abstract (original language)
Background
Inflammatory bowel disease has been linked to increasing healthcare costs, but longitudinal data on other societal costs are scarce.
Aim
To assess costs, including productivity losses, in patients with prevalent Crohn's disease (CD) or ulcerative colitis (UC) in Sweden between 2007 and 2020.
Methods
We linked data from national registers on all patients with CD or UC and a matched (sex, birthyear, healthcare region and education) reference population. We assessed mean costs/year in Euros, inflation‐adjusted to 2020, for hospitalisations, out‐patient visits, medications, sick leave and disability pension. We defined excess costs as the mean difference between patients and matched comparators.
Results
Between 2007 and 2020, absolute mean annual societal costs in working‐age (18–64 years) individuals decreased by 17% in CD (−24% in the comparators) and by 20% in UC (−27% in comparators), due to decreasing costs from sick leave and disability, a consequence of stricter sick leave regulations. Excess costs in 2007 were dominated by productivity losses. In 2020, excess costs were mostly healthcare costs. Absolute and excess costs increased in paediatric and elderly patients. Overall, costs for TNF inhibitors/targeted therapies increased by 274% in CD and 638% in UC, and the proportion treated increased from 5% to 26% in CD, and from 1% to 10% in UC.
Conclusion
Between 2007 and 2020, excess costs shifted from productivity losses to direct healthcare costs; that is, the patients' compensation for sickness absence decreased, while society increased its spending on medications. Medication costs were driven both by expanding use of TNF inhibitors and by high costs for newer targeted therapies.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
- Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Region Stockholm, Stockholm, Sweden.
- Gastroenterology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Gastroenterology Unit, Danderyd Hospital, Stockholm, Sweden.
- Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
ORCID profiles: Åsa H Everhov, Hamed Khalili, Gabriella Bröms, Jonas Halfvarson, Jonas F Ludvigsson
Funding
- Kommunfullmäktige, Stockholms Stad
- Vetenskapsrådet
Cite
APA
Everhov, Å. H., Söderling, J., Befrits, G., Khalili, H., Bröms, G., Neovius, M., SWIBREG study group, Askling, J., Halfvarson, J., Ludvigsson, J. F., & Olén, O. (2023). Increasing healthcare costs in inflammatory bowel disease 2007–2020 in Sweden. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17675
Vancouver
Everhov ÅH, Söderling J, Befrits G, Khalili H, Bröms G, Neovius M, et al. Increasing healthcare costs in inflammatory bowel disease 2007–2020 in Sweden. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17675
BibTeX
@article{Everhov2023,
author = {Everhov, Åsa H and Söderling, Jonas and Befrits, Gustaf and Khalili, Hamed and Bröms, Gabriella and Neovius, Martin and SWIBREG study group, SWIBREG study group and Askling, Johan and Halfvarson, Jonas and Ludvigsson, Jonas F and Olén, Ola},
title = {Increasing healthcare costs in inflammatory bowel disease 2007–2020 in Sweden},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1111/apt.17675}
}
EUVIMED